A risk assessment model for predicting the risk of haemolytic disease of the fetus and newborn (HDFN) in future pregnancies following the transfusion of Rh(D)‐positive red blood cell (RBC)‐containing products… Click to show full abstract
A risk assessment model for predicting the risk of haemolytic disease of the fetus and newborn (HDFN) in future pregnancies following the transfusion of Rh(D)‐positive red blood cell (RBC)‐containing products to females of childbearing potential (FCP) was developed, accounting for the age that the FCP is transfused in various countries.
               
Click one of the above tabs to view related content.